Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06919003 · ClinicalTrials.gov registry record · Phase 2
Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)
A Phase 2 study of Kidney Transplant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 4
- Study locations
NCT06919003: Recruiting Phase 2 study of Kidney Transplant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT06919003 is a Phase 2 study of Kidney Transplant that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 180 participants, below the 1,892-participant average among 30 other Kidney Transplant trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06919003, a Phase 2 study of Kidney Transplant, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to find out if Berinert can improve kidney function in the first year after transplant and to find out what effects, good or bad, Berinert will have in the kidney recipient. This research study will compare Berinert to placebo. The placebo looks exactly like Berinert but does not contain any active drug. Placebos are used in research studies to see if the results are due to the study drug or due to other reasons. Neither you or the study doctor can choose or know which group is assigned. The primary objective is to test whether intrarenal artery C1 esterase inhibitor (C1INH) injection into the donor kidney prior to transplantation improves kidney function in recipients of high risk, deceased donor kidney transplants as measured by 12-month Estimated Glomerular Filtration Rate (eGFR) Chronic Kidney Disease Epidemiology Collaboration (CDK-EPI)
Primary Outcome
Measured as Estimated Glomerular Filtration Rate Chronic Kidney Disease Epidemiology Collaboration (eGFRCKD-EPI) in ml/min/1.73m\^2
Conditions Studied
Interventions
- BIOLOGICAL Berinert
- OTHER Placebo for Berinert
Study Locations (4)
California
- Cedars Sinai Medical Center - Los Angeles
Illinois
- Northwestern Memorial Hospital - Chicago
Kansas
- Kansas University Medical Center - Kansas City
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-09-22 |
| Est. Completion | 2032-05-30 |
| Phase | Phase 2 |
What NCT06919003 shows while recruiting
NCT06919003 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 1,892-participant average among 30 other Kidney Transplant trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Kidney Transplant appearing as the primary indexed condition, and to 2 interventions - of which Berinert is the first listed.
NCT06919003 reports a single indexed study location in California, Illinois, Kansas.
Frequently Asked Questions
What is clinical trial NCT06919003 about?
NCT06919003 is a clinical study titled "Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)". The purpose of this study is to find out if Berinert can improve kidney function in the first year after transplant and to find out what effects, good or bad, Berinert will have in the kidney recipient. This research study will compare Berinert to placebo. The placebo looks exactly like Berinert but...
What is the current status of trial NCT06919003?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2025-09-22. Estimated completion is 2032-05-30.
What conditions does trial NCT06919003 study?
This clinical trial studies the following conditions: Kidney Transplant.
What interventions are being tested in trial NCT06919003?
The interventions under investigation include: Berinert (BIOLOGICAL), Placebo for Berinert (OTHER).
Who is sponsoring clinical trial NCT06919003?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06919003 being conducted?
This trial has 4 study locations across California, Illinois, Kansas, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06919003's enrollment target sits among peer trials
180 9th of 30 higher than 21 of 30 other Kidney Transplant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Transplant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Advancing Transplantation Outcomes in Children
RECRUITING · Phase 2
-
Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation
RECRUITING · Phase 2
-
Sotagliflozin Safety and Tolerability Among Renal Transplant Recipients
COMPLETED · Phase 2
-
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
COMPLETED · Phase 2
-
COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study
COMPLETED · Phase 2
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI